I-MAB (IMAB) EV-to-Revenue : (As of Jun. 24, 2025)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, I-MAB's enterprise value is $35.60 Mil. I-MAB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, I-MAB's EV-to-Revenue for today is .

The historical rank and industry rank for I-MAB's EV-to-Revenue or its related term are showing as below:

During the past 8 years, the highest EV-to-Revenue of I-MAB was 967.85. The lowest was -1859.59. And the median was 1.72.

IMAB's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.6
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-24), I-MAB's stock price is $2.46. I-MAB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, I-MAB's PS Ratio for today is .

I-MAB EV-to-Revenue Historical Data

The historical data trend for I-MAB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EV-to-Revenue Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

11.22

226.96

91.68

-244.47

I-MAB Quarterly Data
	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															314.08	-211.03	-15,909.75	-	-

Competitive Comparison of I-MAB's EV-to-Revenue

For the Biotechnology subindustry, I-MAB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where I-MAB's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

I-MAB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

I-MAB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	35.603	/	0
	=

I-MAB's current Enterprise Value is $35.60 Mil.
I-MAB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

I-MAB (NAS:IMAB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

I-MAB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.46	/	0
	=

I-MAB's share price for today is $2.46.
I-MAB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

I-MAB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of I-MAB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).